U.S. Food and Drug Administration Approves ABRAXANE(R) in Combination with Gemcitabine as First-Line Treatment of Patients with Metastatic Pancreatic Cancer

Approval Based on MPACT Study of ABRAXANE in Combination with Gemcitabine Demonstrating a Clinically Meaningful Increase in Overall Survival First New Treatment Approved for Metastatic Adenocarcinoma of the Pancreas in Nearly 8 Years SUMMIT, N.J.--(H... Biopharmaceuticals, Oncology, FDACelgene, ABRAXANE, paclitaxel, Pancreatic Cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news